Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a regulatory Phase III clinical study. The study will evaluate the combination of the company’s KRAS G12C inhibitor, glecirasib, with Erbitux (cetuximab) for the treatment of colorectal cancer (CRC) with KRAS G12C mutation.
Glecirasib, an in-house developed drug candidate by Jacobio, is currently under investigation in multiple studies across China, the United States, and Europe for various cancer types, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. In collaboration with Germany-based Merck (ETR: MRK), Jacobio will conduct a clinical study combining glecirasib with cetuximab, with Merck providing the cetuximab for the combo trials in both China and Europe.- Flcube.com
